Gilde Healthcare's Buy & Build platform RAD-x acquires medical imaging group to initiate European expansion - Gilde Healthcare

Gilde Healthcare’s Buy & Build platform RAD-x acquires medical imaging group to initiate European expansion

January 24, 2017

RAD-x closes its first transaction: IRD SA, a leading Swiss Diagnostic Imaging Centre

RAD-x announced that it has acquired Geneva-based IRD SA, a leading diagnostic imaging provider. The sellers of IRD SA will reinvest part of the proceeds in the RAD-x holding and join the Gilde Healthcare Services II Fund and RAD-x management as shareholders of the group. IRD SA will continue to be managed by its founding doctors and with the help of RAD-x will invest in expanding its diagnostic capacity.

With this transaction, RAD-x kick-starts its growth model and positions itself as a contender in the fast consolidating European diagnostic imaging market. RAD-x’ operational model is focused on delivering high quality diagnostic imaging services to patients throughout Europe and its growth strategy is funded by Gilde Healthcare, a leader in healthcare private equity. RAD-x is in discussion with several other medical imaging and healthcare groups to expands its presence across Europe; by achieving a critical mass quickly, RAD-x will achieve better conditions in procurement for heavy medical equipment.

Martin HARDENS, Co-founder and CEO of RAD-x:

“I am pleased that we can welcome new partners in this early stage of development of RAD-x. This acquisition initiates our presence in the Swiss diagnostic imaging market. I look forward to working with the management team of IRD in delivering better healthcare for patients.”

Jasper van GORP, managing partner of Gilde Healthcare Services:

“RAD-x is a fast-growing leader with a first-class management team. In a consolidating market, Gilde has been impressed by RAD-x’ commitment to quality and efficiency towards patients and clinicians. We are confident in its capacity to achieve outstanding growth in RAD-x’ core international markets.”

Frank KOLO, Co-founder and Medical Director of IRD SA:

“I am confident that joining RAD-x will open new growth opportunities for IRD. Having a strong partner enables us to expand the diagnostic services we provide to our patients and referring doctors. RAD-x’ support for IRD to invest in two new state of the art MRI-machines and a refurbishment of our most important site is a proof of our joined commitment to continuous improvement in quality of care.”


Contacts:

Jasper van Gorp
Managing Partner
Gilde Healthcare
Tel. +31.30.219.2565
www.gildehealthcare.com

About RAD-x

RAD-x is a pan-European diagnostic imaging platform at the forefront of the outpatient radiology market consolidation in France, Germany and Switzerland. RAD-x’ management team has many years of experience executing radiology and laboratory Buy & Builds. RAD-x’ imaging centers are managed by independent healthcare professionals, all being partners of the group and using shared services to continuously improve their market leading quality and efficiency.
www.rad-x.eu

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing two business lines: lower mid-market buy-out funds (Gilde Healthcare Services) and venture & growth capital funds. The Gilde Healthcare Services Funds invest in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. Gilde’s venture & growth capital funds invest in medtech, diagnostics, digital health and therapeutics. Since 2001 Gilde Healthcare has raised €800 million ($900 million) for its specialized funds.
www.gildehealthcare.com

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023